Nestle to buy Aimmune, valuing allergy treatment maker at $2.6 billion

The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement. The price represents a 174% premium to Aimmune's closing share price on August 28 of $12.60.

from International-News-Economic Times https://ift.tt/3luK0VI
via IFTTT

SHARE